Publication | Open Access

Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial

UrologyGenitourinary CancerMedicineCheckmate 032Immune Checkpoint InhibitorCancer TreatmentOncologyRadiation OncologyMolecular OncologyNivolumab Monotherapy